Theodore Karrison to Hematopoietic Stem Cell Transplantation
This is a "connection" page, showing publications Theodore Karrison has written about Hematopoietic Stem Cell Transplantation.
Connection Strength
0.519
-
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2023 03 28; 7(6):963-970.
Score: 0.138
-
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 07 01; 107(7):1608-1618.
Score: 0.131
-
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
Score: 0.130
-
Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task. Bone Marrow Transplant. 2016 Oct; 51(10):1342-1349.
Score: 0.086
-
The CD34+ cell concentration in peripheral blood predicts CD34+ cell yield in the leukapheresis product. Cytotherapy. 1999; 1(2):141-6.
Score: 0.026
-
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52.
Score: 0.009